Genomic Health, Inc. (GHDX) Reaches $32.74 After 6.00% Down Move; Compass Diversified Holdings (CODI) Has 1.32 Sentiment

February 12, 2018 - By Darrin Black

Compass Diversified Holdings LLC is a private equity firm specializing in acquisitions, buyouts, industry consolidation, recapitalization, and middle market investments. The company has market cap of $982.36 million. It seeks to invest in niche industrial or branded consumer companies, manufacturing, distribution, consumer products, and business services sectors. It currently has negative earnings. The firm prefers to invest in companies based in North America.

The stock of Genomic Health, Inc. (NASDAQ:GHDX) is a huge mover today! The stock decreased 2.33% or $0.78 during the last trading session, reaching $32.74. About 54,648 shares traded. Genomic Health, Inc. (NASDAQ:GHDX) has risen 23.46% since February 12, 2017 and is uptrending. It has outperformed by 6.76% the S&P500.The move comes after 9 months negative chart setup for the $1.14 billion company. It was reported on Feb, 12 by Barchart.com. We have $30.78 PT which if reached, will make NASDAQ:GHDX worth $68.34M less.

Investors sentiment increased to 2.32 in Q3 2017. Its up 0.66, from 1.66 in 2017Q2. It is positive, as 6 investors sold Genomic Health, Inc. shares while 25 reduced holdings. 21 funds opened positions while 51 raised stakes. 30.86 million shares or 1.02% more from 30.55 million shares in 2017Q2 were reported. 135,500 were accumulated by Spark Inv Management Ltd Com. Camber Cap Mgmt Limited Liability Com has 5% invested in Genomic Health, Inc. (NASDAQ:GHDX). The New York-based Amer Gru has invested 0% in Genomic Health, Inc. (NASDAQ:GHDX). Swiss State Bank holds 33,900 shares or 0% of its portfolio. Emory University reported 53,439 shares. National Bank & Trust Of America De invested 0% in Genomic Health, Inc. (NASDAQ:GHDX). Voya Investment Mngmt Llc invested in 8,622 shares or 0% of the stock. Ameritas Inv Ptnrs Inc reported 0% stake. Trust Company Of Vermont accumulated 285 shares or 0% of the stock. Bancorporation Of New York Mellon invested in 90,580 shares. Point72 Asset Mngmt Limited Partnership invested in 0% or 10,900 shares. Deutsche National Bank Ag holds 31,640 shares. State Of Wisconsin Investment Board invested in 0% or 15,000 shares. Gsa Capital Prtn Ltd Liability Partnership reported 63,100 shares or 0.14% of all its holdings. Dubuque Retail Bank And Trust accumulated 0.03% or 5,141 shares.

Among 11 analysts covering Genomic Health (NASDAQ:GHDX), 2 have Buy rating, 3 Sell and 6 Hold. Therefore 18% are positive. Genomic Health has $44 highest and $25.0 lowest target. $33.33’s average target is 1.80% above currents $32.74 stock price. Genomic Health had 31 analyst reports since August 5, 2015 according to SRatingsIntel. Canaccord Genuity maintained it with “Buy” rating and $39.0 target in Wednesday, November 15 report. The firm has “Hold” rating by Jefferies given on Wednesday, August 17. Piper Jaffray downgraded Genomic Health, Inc. (NASDAQ:GHDX) on Monday, January 11 to “Neutral” rating. The rating was maintained by Canaccord Genuity on Monday, August 14 with “Buy”. The stock of Genomic Health, Inc. (NASDAQ:GHDX) has “Hold” rating given on Thursday, August 6 by Zacks. The rating was upgraded by Zacks to “Sell” on Monday, August 24. The firm has “Hold” rating by William Blair given on Wednesday, December 20. The rating was maintained by Jefferies on Friday, October 20 with “Hold”. Barclays Capital initiated the stock with “Underweight” rating in Wednesday, September 2 report. Canaccord Genuity maintained it with “Buy” rating and $42.0 target in Tuesday, January 16 report.

Since August 14, 2017, it had 0 buys, and 10 insider sales for $2.78 million activity. 5,000 shares valued at $151,111 were sold by Popovits Kimberly J on Monday, August 14. Vaughn James J had sold 3,004 shares worth $102,406. On Tuesday, January 9 Cole G Bradley sold $177,566 worth of Genomic Health, Inc. (NASDAQ:GHDX) or 5,000 shares. 5,334 Genomic Health, Inc. (NASDAQ:GHDX) shares with value of $197,298 were sold by Febbo Phillip G.. On Thursday, December 14 Leber Laura sold $699,000 worth of Genomic Health, Inc. (NASDAQ:GHDX) or 21,000 shares.

Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company has market cap of $1.14 billion. It develops and commercializes genomic clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. It currently has negative earnings. The firm offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit.

Analysts await Genomic Health, Inc. (NASDAQ:GHDX) to report earnings on February, 13. They expect $0.09 EPS, up 125.00% or $0.05 from last year’s $0.04 per share. GHDX’s profit will be $3.13M for 90.94 P/E if the $0.09 EPS becomes a reality. After $0.03 actual EPS reported by Genomic Health, Inc. for the previous quarter, Wall Street now forecasts 200.00% EPS growth.

Essex Financial Services Inc. holds 2.72% of its portfolio in Compass Diversified Holdings LLC for 624,166 shares. Gilman Hill Asset Management Llc owns 227,982 shares or 1.66% of their US portfolio. Moreover, Investment Counselors Of Maryland Llc has 0.92% invested in the company for 1.02 million shares. The New York-based Wellington Shields & Co. Llc has invested 0.29% in the stock. Yorktown Management & Research Co Inc, a Virginia-based fund reported 55,000 shares.

It closed at $16.4 lastly. It is down 3.37% since February 12, 2017 and is uptrending. It has underperformed by 13.33% the S&P500.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>